We are live on
!
Find out more
SCM
Sio Capital Management Portfolio holdings
AUM
$604M
1-Year Est. Return
96.57%
This Fund
S&P 500
This Quarter
Est. Return
+12.33%
1 Year Est. Return
+96.57%
3 Year Est. Return
+564.25%
5 Year Est. Return
+486.18%
10 Year Est. Return
+2,856.71%
AUM
$270M
AUM Growth
-$44.3M
(-14%)
Cap. Flow
-$59.3M
Cap. Flow
% of AUM
-21.92%
Top 10 Holdings %
Top 10 Hldgs %
74.66%
Holding
64
New
15
Increased
6
Reduced
6
Closed
18
Avg Time Held Equity + Options
3.9
quarters
Top 10 Avg Time Held Equity + Options
2.1
quarters
Top 20 Avg Time Held Equity + Options
1.6
quarters
Avg Time Held Equity only
4.2
quarters
Top 10 Avg Time Held Equity only
2.8
quarters
Top 20 Avg Time Held Equity only
1.7
quarters
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Medtronic
MDT
|
+$10.4M |
| 2 |
STAAR Surgical
STAA
|
+$9.86M |
| 3 |
Icon
ICLR
|
+$6.74M |
| 4 |
Novavax
NVAX
|
+$6M |
| 5 |
HSKA
Heska Corp
HSKA
|
+$5.68M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Cencora
COR
|
+$31.3M |
| 2 |
GSK
GSK
|
+$23.3M |
| 3 |
Sanofi
SNY
|
+$13.6M |
| 4 |
Centene
CNC
|
+$9.88M |
| 5 |
SkinHealth Systems
SKIN
|
+$7.77M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 59.82% |
| 2 | Miscellaneous | 31.53% |
| 3 | Financials | 8.65% |
| 4 | Consumer Staples | 0% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
|
RXDX
1
PUT
DELISTED
Prometheus Biosciences, Inc. Common Stock
RXDX
| $63.2M | 23.36% |
574,200
+242,000
| +73% | +$15.7M |
2022 Q2
2 quarters
|
|
|
MSAC
2
DELISTED
Medicus Sciences Acquisition Corp. Class A Ordinary Share
MSAC
| $23.4M | 8.65% |
2,323,000
| – | – |
2021 Q4
4 quarters
|
|
3
Bicycle Therapeutics
BCYC
$254M
| $20.2M | 7.48% |
683,425
| – | – |
2021 Q4
4 quarters
|
|
4
Cigna
CI
$74.7B
| $17.4M | 6.45% |
52,611
| – | – |
2020 Q3
9 quarters
|
|
5
Organon & Co
OGN
$3.62B
| $16.4M | 6.07% |
587,836
-41,000
| -7% | -$1.05M |
2022 Q2
2 quarters
|
|
6
United Therapeutics
UTHR
$23.3B
| $15.3M | 5.65% |
54,959
+10,000
| +22% | +$2.52M |
2018 Q4
16 quarters
|
|
7
PUT
Quest Diagnostics
DGX
$25.4B
| $14.4M | 5.32% |
+92,000
| New | +$13.2M |
2022 Q4
0 quarters
|
|
|
8
Cencora
COR
$63B
| $14M | 5.17% |
84,399
-198,000
| -70% | -$31.3M |
2021 Q4
4 quarters
|
|
|
9
Medtronic
MDT
$119B
| $9.95M | 3.68% |
+128,000
| New | +$10.4M |
2022 Q4
0 quarters
|
|
|
10
STAAR Surgical
STAA
$1.08B
| $7.63M | 2.82% |
+157,129
| New | +$9.86M |
2022 Q4
0 quarters
|
|
|
11
Icon
ICLR
$12.7B
| $6.6M | 2.44% |
+33,983
| New | +$6.74M |
2022 Q4
0 quarters
|
|
12
Inogen
INGN
$168M
| $5.65M | 2.09% |
286,692
-234,603
| -45% | -$5.05M |
2021 Q4
4 quarters
|
|
13
Avantor
AVTR
$10.5B
| $5.27M | 1.95% |
+250,000
| New | +$5.18M |
2022 Q4
0 quarters
|
|
|
HSKA
14
DELISTED
Heska Corp
HSKA
| $5.24M | 1.94% |
+84,309
| New | +$5.68M |
2022 Q4
0 quarters
|
|
15
Protagonist Therapeutics
PTGX
$8.96B
| $4.74M | 1.75% |
+434,635
| New | +$3.67M |
2022 Q4
0 quarters
|
|
|
16
Novavax
NVAX
$2.11B
| $3.5M | 1.29% |
+340,000
| New | +$6M |
2022 Q4
0 quarters
|
|
17
DELISTED
Cymabay Therapeutics
CBAY
| $3.48M | 1.29% |
555,610
| – | – |
2020 Q1
11 quarters
|
|
18
Pharvaris
PHVS
$2.11B
| $3.21M | 1.19% |
+285,000
| New | +$1.5M |
2022 Q4
0 quarters
|
|
19
DELISTED
Merrimack Pharmaceuticals, Inc.
MACK
| $2.87M | 1.06% |
+250,000
| New | +$2.06M |
2022 Q4
0 quarters
|
|
|
RETA
20
PUT
DELISTED
Reata Pharmaceuticals, Inc. Class A Common Stock
RETA
| $2.55M | 0.94% |
+67,000
| New | +$2.31M |
2022 Q4
0 quarters
|
|
21
Orchestra BioMed
OBIO
$344M
| $2.5M | 0.92% |
250,000
| – | – |
2020 Q3
9 quarters
|
|
|
EUCRU
22
DELISTED
Eucrates Biomedical Acquisition Corp. Unit
EUCRU
| $2.48M | 0.92% |
248,674
| – | – |
2020 Q4
8 quarters
|
|
|
CTIC
23
DELISTED
CTI BioPharma Corp. (DE) Common Stock
CTIC
| $1.98M | 0.73% |
+330,000
| New | +$1.8M |
2022 Q4
0 quarters
|
|
|
ISEE
24
PUT
DELISTED
IVERIC bio, Inc. Common Stock
ISEE
| $1.85M | 0.68% |
86,400
| – | – |
2022 Q2
2 quarters
|
|
25
X4 Pharmaceuticals
XFOR
$258M
| $1.81M | 0.67% |
60,865
+13,583
| +29% | +$643K |
2021 Q1
7 quarters
|
|
Similar funds
EFL
V
MAM
RCM
AMG
VV
VCP
EHI
Sio Capital Management's Q4 2022 Portfolio in Review
As of Q4 2022, Sio Capital Management held 64 positions worth $270M, down 14% from $315M the previous quarter. Its ten largest holdings account for 75% of the portfolio.
Sio Capital Management withdrew a net $59.3M in Q4 2022, closing 18 positions and reducing 6 holdings. Its most notable exit was GSK, an estimated $23.3M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 60% of assets, down from 64% a quarter earlier, followed by Miscellaneous and Financials.
Against the trend, Sio Capital Management opened a new position in Medtronic worth $9.95M.
- Sio Capital Management's largest Q4 2022 buy was Medtronic: 128,000 shares worth $9.95M.
- Sio Capital Management added most to United Therapeutics in Q4 2022, an estimated $2.52M increase.
- Sio Capital Management's biggest Q4 2022 reduction was Cencora, cutting an estimated $31.3M.
- Sio Capital Management fully exited GSK in Q4 2022, selling an estimated $23.3M.
- Sio Capital Management's ten largest holdings make up 75% of its $270M portfolio in Q4 2022.
- Sio Capital Management opened 15 new positions and closed 18 in Q4 2022.
- Sio Capital Management's portfolio value fell 14% quarter-over-quarter to $270M.
Based on Sio Capital Management's 13F filing for Q4 2022, filed 13 Feb 2023.